Barclays raised the firm’s price target on Twist Bioscience (TWST) to $39 from $37 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the “most under-owned space in healthcare” creates a “great setup” for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Private Markets: Prediction market platform Kalshi secures $300M
- Twist Bioscience Faces Scaling Challenges: Potential Impact on Future Demand and Financial Health
- Cathie Wood Cuts Stake in Pinterest Stock (PINS), Loads Up on Bitmine (BMNR) and Biotech Stocks
- Twist Bioscience price target lowered to $37 from $40 at Barclays
- Twist Bioscience Reports Record Revenue and Growth